Bayer has stepped back from a confrontation it initiated barely two weeks earlier. The group’s subsidiary Ruveon withdrew its petitions for antidumping duties on Chinese glyphosate on July 17, just days after filing them. The move signals an acceptance of market-driven pricing rather than an escalation of trade protectionism. The stock closed at €48.06 on Friday, down 4.34% on the week and 10.77% below its 52-week high of €53.86, reached on July 3.
The retreat leaves Bayer exposed to the very problem the tariff request was meant to solve. As the only remaining U.S. producer of glyphosate, the company faces relentless price pressure from cheap Chinese generics — a challenge CEO Bill Anderson had previously warned could force an end to domestic production. With the tariff petition withdrawn, that structural weakness remains, and Bayer itself expects glyphosate sales to fall by 2% to 6% in 2026. The group’s decision to revert to a dynamic pricing model tied to generic market rates suggests margins in the Crop Science division will stay under scrutiny when quarterly results are released.
Legal developments have offered a counterweight, though not without complications. The U.S. Supreme Court ruled 7-2 that consumers cannot sue Bayer over the absence of a cancer warning on glyphosate labels as long as the Environmental Protection Agency does not require one, overturning a $1.25 million verdict. The decision removes a major liability overhang after nearly a decade of litigation that has cost Bayer more than $10 billion. However, a fairness hearing for the $7.25 billion class-action settlement covering a large portion of outstanding Roundup claims was postponed from early July to August 19, 2026, injecting a fresh element of uncertainty. JPMorgan affirmed its “Overweight” rating and €50 target on the stock following the Supreme Court ruling, noting that the legal relief is now largely priced in.
Bayer has also been shoring up its balance sheet. On July 17 it completed a $5 billion bond placement to refinance existing debt, and earlier in the month it secured €3 billion in equity from Apollo Global Management in exchange for a minority stake in a new entity housing its reversible long-acting contraceptive business. Despite these moves, Fitch Ratings affirmed Bayer’s BBB long-term issuer rating with a negative outlook on July 13, citing high net debt and persistent cash flow strains. Free cash flow turned negative in the first quarter and net financial debt rose, while the stock’s 30-day annualized volatility of 62% reflects lingering market anxiety.
Should investors sell immediately? Or is it worth buying Bayer?
Analyst opinion remains split on the stock’s trajectory. Barclays raised its target to €60 on July 14, maintaining “Overweight,” while Berenberg lifted its price objective to €55 but kept a “Hold” rating, citing the improved optionality of a potential future breakup. Jefferies took a more cautious stance, reiterating “Hold” with a €46 target. Meanwhile, French asset manager Amundi disclosed a stake exceeding 3% of voting rights, now holding 3.09% or 30,375,174 votes.
Beyond the legal and pricing battles, Bayer is advancing long-term growth projects. On July 15 it signed an exclusive licensing agreement with French firm RAGT to develop hybrid wheat, targeting market entry in the early 2030s and potential peak revenue of €1 billion by the mid-2040s. The group also reported a solid first quarter, with revenue and EBITDA growing and the full-year guidance confirmed and slightly raised.
The near-term direction hinges on two factors. First, the operational recovery in Crop Science and Pharmaceuticals must hold. Second, the legal relief from the Supreme Court must not be undermined by renewed price erosion in glyphosate. If both conditions are met, the broader recovery story — the stock is up 72.29% over twelve months and 29.86% year-to-date — remains intact. If the tariff retreat proves to be a harbinger of margin deterioration, the gap to the 52-week high may widen again. Investors will get their next clue on August 4, when Bayer publishes its half-year report, followed by the rescheduled Missouri hearing on August 19.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from July 18 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 18.
Bayer: Buy or sell? Read more here...
